Good point… if there was indeed an 5-ALA effect, it would have been in the year or two.
Maybe they were able to make more vaccine doses later in the trial, than they had been able to previously. There was someone here on the board (Lady Gray) who had people posted something about this awhile back, and there was some discussion on the board about it. I don’t really know what could have accounted for the increase in survival in the last 108 patients… but I don’t believe that it was due to all patients crossing over to treatment due to an efficacy finding by the FDA that was completely hidden from the company.
Market Data 
Markets 
AI
